10-K: Sensus Healthcare Reports 2025 Net Loss Amid Revenue Decline

Sensus Healthcare, Inc. reported a net loss of $7.7 million in 2025, a significant decline from the prior year's profit, driven by reduced sales and increased operating expenses.

Summary

• Reported a net loss of $7.7 million for the year ended December 31, 2025, a reversal from a net income of $6.6 million in 2024.
• Revenues decreased by 34% to $27.5 million in 2025 from $41.8 million in 2024, primarily due to a lower number of units sold (70 in 2025 vs. 115 in 2024) and reduced sales to the largest customer.
• Gross profit declined by 51% to $11.9 million (43.3% of revenue) in 2025 from $24.4 million (58.4% of revenue) in 2024, impacted by lower sales and higher servicing costs.
• Total operating expenses increased by 35.7% to $22.2 million in 2025 from $16.3 million in 2024.
• Research and development expenses surged by 86% to $7.8 million in 2025, mainly due to significant lobbying costs for billing code reimbursement and product development for next-generation systems.
• Selling and marketing expenses increased by 30% to $6.5 million, driven by higher tradeshow costs and increased headcount.
• General and administrative expenses rose by 11% to $7.9 million, primarily due to increased professional fees, insurance, and compensation costs.
• Cash and cash equivalents remained stable at $22.1 million at December 31, 2025, compared to $22.0 million at December 31, 2024.
• Accounts receivable, net, decreased by 70% to $6.0 million at December 31, 2025, from $19.7 million at December 31, 2024, largely due to decreased sales and extended payment terms with the largest customer.
• Inventories increased by 44% to $14.6 million at December 31, 2025, from $10.1 million at December 31, 2024, in anticipation of increasing future sales.
• The company was in default of its revolving credit facility covenant for failing to maintain minimum profitability as of December 31, 2025.
• A single U.S. customer accounted for 52% of revenues in 2025 and 73% in 2024.
• 92% of total revenue in 2025 originated from the United States, with 7% from China and 1% from other regions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period marked by a significant net loss and revenue decline, coupled with a credit facility covenant default. While new product launches and CPT codes offer future potential, current financial performance is a major concern.

Positives

• CMS released new CPT codes for Superficial Radiation Therapy (SRT) effective January 1, 2026, which management expects to increase demand for the SRT product.
• Launched Sensus Healthcare Financial Services in February 2026, a financing program through third-party banks to support system acquisitions and reduce administrative barriers.
• Introduced Sensus Link in February 2026, a cloud-based software solution designed to expand advanced operating capabilities across the SRT-100 system installed base.
• Formed Sensus Healthcare Services, LLC in February 2024, a wholly-owned subsidiary providing operational healthcare offerings and a recurring revenue 'Fair Deal Agreement' service model.
• Obtained Medical Device Single Audit Program (MDSAP) certification, which streamlines regulatory compliance and market access in USA, Canada, Japan, Australia, and Brazil.
• Successfully remediated a material weakness in internal control over financial reporting identified in the second quarter of 2024.

Negatives

• Reported a net loss of $7.7 million in 2025, a significant decline from the $6.6 million net income in 2024.
• Total revenues decreased by 34% year-over-year, from $41.8 million in 2024 to $27.5 million in 2025.
• Gross profit margin significantly declined from 58.4% in 2024 to 43.3% in 2025.
• Was in default of a minimum profitability covenant under its revolving credit facility as of December 31, 2025.
• Experienced a substantial concentration of sales to one U.S. customer, accounting for 52% of revenues in 2025 and 73% in 2024.
• Two U.S. patents (U.S. Patent No. 7,372,940 and U.S. Patent No. 7,263,170) related to radiation therapy systems expired on September 30, 2025.
• The announcement of new CPT codes, effective January 1, 2026, significantly impacted 2025 sales as customers delayed purchases in anticipation of the new codes.

Risks

• If third-party payors do not provide coverage and adequate reimbursement for the use of products, product adoption and revenue will be negatively impacted.
• Substantially all revenue is generated from the sale of the SRT-100 and related products, making the company vulnerable to any decline in these sales.
• The company's technology could be superseded by new products, treatments, or technologies developed by competitors.
• Customer concentration in the U.S. and China, with one U.S. customer accounting for a significant portion of sales, poses a risk to revenue stability.
• Reliance on a single preferred supplier for x-ray tubes and other major components could adversely affect production and revenues if the supplier is lost or unable to meet demand.
• Operations may be impaired if information technology systems fail or are subject to data breaches or cyberattacks.
• May be required to obtain additional funds in the future, which may not be available on acceptable terms or at all, potentially leading to dilution or restrictive debt covenants.
• Consolidation in the healthcare industry could adversely affect future revenues and operating income.
• Pandemics, natural disasters, global climate change, acts of terrorism, and global conflicts may negatively impact business and operations.
• Subject to various federal, state, and foreign healthcare laws and regulations, and non-compliance could result in significant penalties.
• Required to comply with medical device reporting requirements, and failure to do so or any necessary corrective actions could harm reputation and financial results.
• Healthcare policy changes, including cost containment measures, may have a material adverse effect on the business.
• If patents and other intellectual property rights do not adequately protect products, the company may lose market share to competitors.
• The medical device industry is characterized by extensive patent litigation, which could be costly and divert management's attention.
• Adverse outcomes in litigation or similar proceedings could negatively impact business.
• History of net losses and the risk of not returning to or maintaining profitability could negatively impact financial condition and stock value.
• Limited trading activity for common stock may contribute to price volatility.
• Does not anticipate paying dividends for the foreseeable future, requiring investors to rely on price appreciation.
• Executive officers and directors may exert control over the company and influence stockholder approval matters.
• Lack of or unfavorable research by securities or industry analysts could cause the stock price and trading volume to decline.
• Corporate governance provisions and Delaware law could discourage acquisitions and prevent stockholders from replacing directors and management.
• The exclusive forum provision in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate and timely financial statements and harm investor views.

Future Outlook

Management expects that the new CPT codes for Superficial Radiation Therapy (SRT), effective January 1, 2026, will increase demand for the SRT product. The company aims to return to profitability in 2026 by increasing sales and managing operational expenses, while continuing to invest in marketing initiatives. Research and development expenses are projected to be substantially lower in 2026 compared to 2025.

Management Comments

• "Sensus continues to seek to return to profitability in 2026 by, among other things, increasing sales and managing operational expenses where necessary in order to continue to invest in marketing initiatives to promote the Company’s products."
• "Management expects that the new reimbursement codes will increase the demand for the SRT product."
• "The Company expects research and development expenses incurred in 2026 to be substantially lower than those incurred in 2025."

Industry Context

StockSavvy.ai notes that the medical device industry is highly competitive and subject to rapid technological change. Sensus Healthcare's focus on non-melanoma skin cancer and keloid prevention with SRT technology positions it in a specialized market segment. The introduction of new CPT codes for SRT by CMS is a significant regulatory development that could reshape market dynamics and reimbursement for superficial radiation therapy, potentially increasing adoption among healthcare providers. The company's recent launches of Sensus Healthcare Financial Services and Sensus Link are strategic moves to enhance market penetration and customer retention in a competitive landscape, aiming to reduce administrative and financing barriers and expand advanced operating capabilities.

Corporate Governance

Legal Proceedings

• Received a Civil Investigative Demand from the Department of Justice in August 2019 concerning an investigation into Medicare billing by a physician using the SRT-100.
• The Department of Justice is considering expanding the investigation to determine the company's involvement in the physician's use of certain reimbursement codes.
• The company disputes any wrongdoing and believes it has strong and meritorious defenses, stating it does not submit claims for reimbursement or provide coding/billing advice.
• As of December 31, 2025, the company was unable to estimate the cost, if any, associated with this matter.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and must rely on price appreciation for returns due to no anticipated dividends. The concentration of ownership by executive officers and directors, along with anti-takeover provisions, could influence corporate decisions.
• Customers may benefit from increased access to SRT technology through new financing options (Sensus Healthcare Financial Services) and enhanced operational capabilities via Sensus Link. New CPT codes are expected to increase demand for SRT products.
• Employees have seen increased headcount in sales, marketing, and R&D, with competitive compensation offered to attract and retain key personnel. Stock-based compensation is a component of employee incentives.
• Creditors, specifically Comerica Bank, are impacted by the company's default on a minimum profitability covenant under its revolving credit facility as of December 31, 2025.
• Suppliers, particularly the single preferred supplier for x-ray tubes, are critical to the company's operations, though efforts are being made to diversify with additional third-party suppliers like Koplak, LLC.

Next Steps

• Return to profitability in 2026 by increasing sales and managing operational expenses.
• Continue to invest in marketing initiatives to promote products.
• Monitor geopolitical developments for potential business impact.
• Evaluate any impact on the credit facility due to Comerica Bank's acquisition by Fifth Third.
• Evaluate ASU No. 2024-03 and ASU No. 2025-11 to determine their impact on consolidated financial statements.
• Establish a dedicated cybersecurity governance committee.
• Standardize cybersecurity incident response procedures and formats.
• Conduct penetration tests on a quarterly basis.
• Enhance segregation of duties to mitigate the risk of self-review of transactions within the system.

Key Dates

Recommendation

The significant decline in revenue and a return to a net loss in 2025, coupled with a default on a credit facility covenant, indicates substantial operational and financial challenges. While the new CPT codes and recent product/service launches offer potential for future growth and improved demand, the immediate financial performance is concerning. The high customer concentration and expiring patents also present risks. A 'hold' recommendation is appropriate as investors should monitor the impact of the new CPT codes and the company's ability to return to profitability and address its covenant default before considering further investment.

Keywords

Sensus Healthcare, SRT, superficial radiation therapy, non-melanoma skin cancer, keloids, medical device, dermatology, radiation oncology, 10-K, SEC filing, financial results, revenue, net loss, CPT codes, Fair Deal Agreement, Sensus Link, intellectual property, cybersecurity, healthcare regulation